Faculty
|
|
Matthew ALBERT Our lab focuses on the characterization of the cellular and molecular mechanisms underlying the cross-priming of tumor and viral-specific cytolytic T lymphocytes (CTLs). To achieve this goal and maintain a strong link to physiologic and pathologic problems, the laboratory is organised using a bedside-to-bench approach to biomedical research. |
|
|
Andrès ALCOVER We investigate the molecular mechanisms that generate immunological synapses and their role in T cell activation. We also study how lymphotropic retroviruses subvert these mechanisms to modulate T cell responses and to spread efficiently from cell to cell. |
|
|
Philippe BOUSSO We are studying how cell contacts established by T cells or NK cells are regulated in vivo and how these interactions modulate the efficiency of immune responses against tumors or pathogens. |
|
|
Pierre BRUNHS Our aim is to decipher the role of human antibodies, human antibody receptors (FcRs) and the cells expressing them during therapy (anti-tumor antibody therapy) and in the induction of antibody-related pathologies. We address these questions by using models of allergy, autoimmunity (arthritis, thrombocytopenia) and cancer immunotherapy in mice "humanized" for their antibodies and FcRs. We also develop translational projects with the clinic to study the role of antibodies in allergic shock (projects NASA and IPAAQ). |
|
|
Ana CUMANO Hematopoietic cell development occurs through a succession of events involving hematopoietic stem cell generation, self-renewal, lineage commitment and differentiation. The different members of the Unit for Lymphocyte Development study in an integrative manner different aspects of hematopoietic and lymphocyte development. |
|
|
James DI SANTO Our research aims to define the molecular signals that drive lymphocyte development and control lymphocyte homeostasis, in order to know how these signals can potentially impact and regulate immune responses. A main area of interest involves deciphering the genetic program of NK cell differentiation in both mice and man. A second group develops humanized mice to model human disease. |
|
|
Caroline DEMANGEL Immunobiology of Infection
Our aims are to develop innovative approaches to fight mycobacterial infections and advance our understanding of the host immune responses to these important pathogens. Mycobacteria indeed represent challenges to global health, with Mycobacterium tuberculosis infecting nearly one-third of the world’s population, the incidence of M. leprae infections persisting at high levels despite control programs and M. ulcerans causing the third most common mycobacterial disease and an emerging public health threat, Buruli ulcer. To establish host residence these species have evolved complex lipids that are strategically located at the interface with the immune system and play dual roles in bacterial virulence and host immunomodulation. Our objectives are to study the molecular mechanisms by which they operate, mine bacterial lipidomes for novel immunomodulatory compounds, and eventually translate our basic knowledge of these natural products into medical treatments against mycobacterial infections and inflammatory pathologies. |
|
|
Ludovic DERIANO Lymphocyte Development and Oncogenesis
Our research focuses on understanding the mechanisms by which a cell maintains the integrity of its DNA and prevents genomic instability and transformation. More precisely, our lab studies the DNA recombination processes that are part of B- and T-cell development and the mechanisms and pathways that lead to lymphoid cancers. Research keywords: lymphocyte development, cancer, mouse models, genome stability, DNA repair, DNA damage.
|
|
|
Gérard EBERL Our projects aim at understanding the impact of symbiotic microbiota and inflammation on the development of the immune system. In particular, we dissect the role of innate lymphoid cells and active stromal cells in homeostasis and disease. |
|
|
Antonio FREITAS |
|
|
Claude LECLERC The activity of our laboratory is focused on the understanding of the mechanisms that control the activation and regulation of T cell responses and on the development of new strategies of vaccination against tumors and infections. |
|
|
Sandra PELLEGRINI Our research centers on the molecular mechanisms of type I IFN action, with particular attention to receptor and Jak tyrosine kinases functioning, differential activities of IFNα2 and IFNβ, and mechanisms leading to cell desensitization. We also study how type I IFNs modulate human T cell activation and effector function. |
|
|
Lars ROGGE Our lab studies the molecular mechanisms that control the differentiation and function of human helper T cell subsets, and analyzes their roles in infectious and inflammatory diseases. |
